SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001193125-22-222028
Filing Date
2022-08-16
Accepted
2022-08-16 12:20:29
Documents
1
Group Members
ALBERT CHADANIEL ESTESFHMLS IX, L.L.C.FHMLS IX, L.P.FHMLS XI, L.L.C.FHMLS XI, L.P.FHMLSP, L.L.C.FHMLSP, L.P.FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.FRAZIER LIFE SCIENCES XI, L.P.JAMES BRUSHJAMES TOPPERPATRICK HERON

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d346331dsc13da.htm SC 13D/A 347226
  Complete submission text file 0001193125-22-222028.txt   349158
Mailing Address 601 UNION STREET SUITE 3200 SEATTLE WA 98101
Business Address 601 UNION STREET SUITE 3200 SEATTLE WA 98101 206-254-7200
Frazier Life Sciences IX, L.P. (Filed by) CIK: 0001720320 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404
Business Address 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404 650-667-4085
Mirum Pharmaceuticals, Inc. (Subject) CIK: 0001759425 (see all company filings)

IRS No.: 831281555 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91075 | Film No.: 221169166
SIC: 2834 Pharmaceutical Preparations